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ORIGINAL RESEARCH ARTICLE
TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer
therapy
ZhengQiang Yuan, Krishna K. Kolluri, Kate H. C. Gowers and Sam M. Janes
Lungs for Living Research Centre, UCL Respiratory, Division of Medicine, University College London, London, UK
ABSTRACT
Extracellular vesicles (EVs) are lipid membrane-enclosed nanoparticles released by cells. They
mediate intercellular communication by transferring biological molecules and therefore have
potential as innovative drug delivery vehicles. TNF-related apoptosis-inducing ligand (TRAIL)
selectively induces apoptosis of cancer cells. Unfortunately, the clinical application of recombi-
nant rTRAIL has been hampered by its low bioavailability and resistance of cancer cells. EV-
mediated TRAIL delivery may circumvent these problems. Mesenchymal stromal cells (MSCs)
produce EVs and could be a good source for therapeutic EV production. We investigated if
TRAIL could be expressed in MSC-derived EVs and examined their cancer cell-killing efficacy. EVs
were isolated by ultracentrifugation and were membranous particles of 50–70 nm in diameter.
Both MSC- and TRAIL-expressing MSC (MSCT)-derived EVs express CD63, CD9 and CD81, but only
MSCT-EVs express surface TRAIL. MSCT-EVs induced apoptosis in 11 cancer cell lines in a dose-
dependent manner but showed no cytotoxicity in primary human bronchial epithelial cells.
Caspase activity inhibition or TRAIL neutralisation blocked the cytotoxicity of TRAIL-positive
EVs. MSCT-EVs induced pronounced apoptosis in TRAIL-resistant cancer cells and this effect
could be further enhanced using a CDK9 inhibitor. These data indicate that TRAIL delivery by
MSC-derived EVs is an effective anticancer therapy.
ARTICLE HISTORY
Received 26 July 2016
Revised 28 September 2016








Extracellular vesicles (EVs) are cell-released submicron
membranous vesicles composed of lipids, proteins and
nucleic acids. Increasing evidence demonstrates that
EVs have a vital role in mediating intercellular com-
munication via transfer of biological molecules from
donor cells to neighbouring or distant recipient cells in
both physiological and pathological conditions [1–8].
There are in general three types of EV, exosomes,
microvesicles and apoptotic bodies, which are classified
according to their biogenesis [8–10]. Originating from
endosomal compartments, exosomes are generated by
intact cells through intra-luminal budding of multive-
sicular bodies (MVBs) and are released to the extra-
cellular environment when MVBs move to and fuse
with the plasma membrane. Exosomes are relatively
homogenous in size, ranging from 30 nm to 150 nm
in diameter, and contain marker proteins such as tetra-
spanins CD9, CD63 and CD81, flotillin, ALG2-inter-
acting protein X (ALIX) and tumour susceptibility gene
101 protein [8,10,11]. By contrast, microvesicles are
derived by direct outward budding and fission of the
plasma membrane, are characterised by varying sizes
between 50 nm and 2000 nm in diameter and display
surface markers of the cells from which they originate
[10]. Apoptotic bodies come from outward blebbing of
the plasma membrane of apoptotic cells, with sizes
ranging from 50 nm to 5000 nm in diameter, and are
characterised by extensive exposure of phosphatidyl-
serine on the surface [10]. Currently, EV studies have
mainly focused on exosomes and microvesicles because
of their essential roles in modulating cell behaviour and
fate.
As natural nanoscale agents, EVs can infiltrate tis-
sues and can even penetrate the blood–brain barrier;
thus, they have therapeutic potential as drug delivery
vehicles [11–13]. Indeed, increasing numbers of studies
have used EVs to deliver anticancer microRNAs
(miRNAs) and proteins [14,15]. Several Phase I studies
using EVs were completed in the early 21st century and
no grade II toxicity or maximal tolerated dose was
found, indicating the safety of EV administration
[13,16–18].
Although most, if not all, cells release EVs,
mesenchymal stromal cell (MSC)-derived EVs (MSC-
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EVs) may have advantages for drug delivery.
Compared with other cell types, MSCs produce many
EVs and show sustainable and reproducible EV pro-
duction [19]. MSC-EVs have good stability in human
plasma and during storage at −20°C [20,21], and they
have high flexibility for modification in vitro and in
vivo [14,22,23]. In addition, unmodified MSC-EVs
have shown encouraging therapeutic effects and are
well tolerated in various animal models [8,24–26]. For
example, MSC-EVs have been used to alleviate liver
fibrosis [25], reduce myocardial infarct size [27] and
ameliorate induced allergic airway inflammation in
immunocompetent mice [28].
Tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) is a promising anticancer
protein that binds to its cognate death receptor 4
(DR4) or DR5 on target cells, resulting in apoptosis
induction in transformed or cancerous cells but not in
normal cells [29,30]. It is safe to deliver the agent for
therapeutic interventions, with the ligand exhibiting no
detectable cytotoxicity to normal tissues in murine and
primate models [31,32] or in humans [33]. The protein
in its soluble recombinant form (rTRAIL) has been
extensively tested as a cancer therapeutic agent in
vitro and in clinical trials [31,32,34–38]. However, the
therapeutic benefits have been limited [39], possibly
due to its poor pharmacokinetics and cancer cell resis-
tance [39]. To overcome these shortcomings, efficient
TRAIL delivery is essential. We sought to investigate
whether MSC-EVs are a good candidate for this pur-
pose. In this study we therefore sought to express
TRAIL on MSC-EVs and tested the efficacy of
TRAIL-loaded EVs on cancer-cell killing.
Methods and materials
Cell culture
Cell culture reagents were purchased from Invitrogen
unless otherwise stated. Eleven cancer cell lines were
tested, including 3 lung cancer lines (A549, NCI-H460
and NCI-H727), 4 malignant pleural mesothelioma
lines (H2795, H2804, H2810 and H2818), 2 renal can-
cer lines (RCC10 and HA7-RCC), 1 human breast
adenocarcinoma line (MDAMB231; M231) and 1 neu-
roblastoma line (SHEP-TET). A549 and M231 were
obtained from Cancer Research UK. Other cell lines
were kind gifts from Dr Ultan McDermott in
Wellcome Trust Sanger Institute, Cambridge, UK.
NCI-H460 and H2810 were cultured in RPMI-1640
medium with 10% foetal bovine serum (FBS); RCC-10
cells were cultured in DMEM/F-12 with 10% FBS; and
all other cell lines were grown in DMEM containing
10% FBS. Well-characterised human adult MSCs (pas-
sage 1) were purchased from Texas A&M Health
Science Centre. TRAIL-transduced MSCs
(MSCTRAIL cells) were previously established by
transduction of MSCs with lentiviruses expressing
human TRAIL [40]. Both MSCs and MSCTRAIL cells
were routinely cultured and maintained in α-MEM
medium containing 17% FBS. For the isolation of
MSC- and MSCTRAIL-derived EVs, cells were cul-
tured in α-MEM medium containing 10% EV-depleted
FBS (Cambridge Bioscience). Primary human lung
bronchial epithelial cells (HBECs) were previously
established in the laboratory [41] and cultured in
DMEM/Ham F-12 with additives following the
reported description [42].
Isolation of EVs
To prepare cell-derived EVs, early passage MSCs and
MSCTRAIL cells (not older than passage 5) were first
cultured in α-MEM medium containing 17% FBS until
cells reached 70–80% confluence; then the medium was
changed to α-MEM containing 10% EV-depleted FBS
(Cambridge Bioscience) for a further 48 hours. Cell-
conditioned medium was then collected and centri-
fuged for 10 min at 300 × g and then again at
2000 × g at 4°C to remove cells and debris, followed
by vacuum filtering the medium through 0.22 μm
filters (Merck Millipore) to remove large vesicles, con-
centrating the medium five times using 100-kDa
MWCO centrifugal filtering columns (Merck
Millipore, UK) and finally ultracentrifuging for
2 hours at 100,000 × g at 4°C. The obtained EV pro-
ducts were washed twice with 0.22 μm membrane-
filtered phosphate-buffered saline (PBS) and finally
resuspended in PBS for storage in −80°C until use.
Alternatively, the isolated EVs were lysed in EV lysis
buffer for quantification using a commercial EV quan-
tification kit (EXOCET96A-1, Cambridge Bioscience,
UK); for Western blotting, the isolated EVs were lysed
in radio immunoprecipitation assay (RIPA) buffer sup-
plemented with protease inhibitor cocktail (Sigma-
Aldrich). EV protein yields were determined by using
a bicinchoninic acid (BCA) protein assay following the
manufacturer’s instructions.
Transmission electron microscopy (TEM)
Isolated EVs suspended in PBS were absorbed on for-
mvar/carbon-coated nickel grids for 10 min and
unbound EVs were washed away with 0.1× PBS.
Grids were then fixed in 1% glutaraldehyde for
10 min and negatively stained with 0.3% uranyl acetate
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in 1.9% ethylcellulose. Excess fluid was removed and
grids were air dried before examination and imaging
with a Tecnai T12 electron microscope (FEI,
Eindhoven, Netherlands).
EV labelling and cell uptake assay
EVs were labelled with the green lipid membrane dye
PKH67 (Sigma-Aldrich) for cell uptake and visualised
or labelled with fluorescent-conjugated antibodies that
are specific for proteins expressed in EVs. For PKH67
labelling, 3 µg of EVs were stained with 2 µM PKH67
for 5 min at room temperature and then dialysed in
PBS for 24 h to remove free dye using a D-tube dialyser
(6–8 kDa) (Novagen). For direct immunofluorescence
staining, EVs were first incubated with PBS containing
0.2% bovine serum albumin (BSA), followed by incu-
bation with a fluorescein isothiocyanate (FITC)-conju-
gated mouse anti-human CD63 antibody (MCA2142F,
AbD Serotec, UK), or with isotype control antibodies
for 1 h at 4°C. Subsequently, the labelled EVs were
washed with PBS and precipitated with a commercial
EV precipitation solution (ExoQuick-TC, Cambridge
Biosciences, UK) to remove unbound antibodies. EVs
labelled by FITC-conjugated anti-CD63 antibody were
analysed for CD63 expression by flow cytometry; those
stained with PKH67 were applied to M231, H2795,
A549 and H2810 cells for cellular uptake experiments.
In brief, recipient cells were cultured in normal culture
medium in wells of chamber slides (Nunc Lab-Tek)
and PKH67-labelled EVs or -control PBS were added
to wells at 3 µg/ml and incubated for 1 h at 37°C in a
5% CO2 incubator. Medium was then removed and
cells were washed three times with PBS. Afterwards,
cells were fixed for 10 min using 4% paraformaldehyde,
washed, mounted with the ProLong Gold Antifade
Reagent with DAPI (Invitrogen, UK) and analysed
using confocal microscopy (Leica TCS SP2 micro-
scope). For uptake quantification, after washing, cells
were subject to fluorescence-activated cell sorting
(FACS) analyses.
Flow cytometry
Flow cytometry analysis was performed to examine
protein expression on the EV surface membrane. For
the detection of CD63 expression, EVs were labelled
with the FITC-conjugated mouse anti-human CD63
antibody (MCA2142F, AbD Serotec, UK), or with a
FITC-conjugated mouse isotype IgG (MCA928F, AbD
Serotec, UK) and gated as previously described [43].
Alternatively, the isolated EVs were first purified for
CD63+ vesicles by binding to magnetic Dynabeads
coated with a human CD63 antibody (Cat:10606D,
Invitrogen), then labelled with Alexa Fluor 647
(AF647)-conjugated antibodies or PE-conjugated anti-
bodies and analysed for TRAIL and tetraspanin (CD63,
CD9 and CD81) expression by flow cytometry.
Antibodies used include AF647-conjugated mouse
anti-human CD63 (H5C6, BD Pharmingen), AF647-
conjugated mouse IgG1 k isotype control (MOPC-21,
BD Pharmingen), PE-conjugated mouse anti-human
CD9 (Cat:555372, BD Pharmingen), PE-conjugated
mouse anti-human CD81 (Cat:555676, BD
Pharmingen), PE-conjugated mouse anti-human
CD63 (Cat:557305, BD Pharmingen) and PE-conju-
gated mouse IgG1 k isotype control (Cat:559320, BD
Pharmingen). PE-conjugated anti-human DR4 anti-
body (Cat: 564180, BD Pharmingen), PE mouse anti-
DR5 (Cat: 565499, BD Pharmingen) and PE mouse
IgG1 isotype (Cat: 559320, BD Pharmingen) were
used to label cellular surface DR4 and DR5. FACS
median fluorescence intensity (MFI) of labelled cells
was used to quantitate EV or cellular surface protein
expression levels or measure cell uptake of EVs labelled
by green lipid membrane dye PKH67.
Western blot analysis
MSCTRAIL cells or EVs were lysed in RIPA buffer for
total protein extraction and the protein concentration
in the lysate was determined using a BCA protein
assay. 30 µg of cellular lysate proteins or 20 µg of EV
proteins for each sample were resolved on 4–12% poly-
acrylamide sodium dodecyl sulphate gels and analysed
by means of immunoblotting with primary rabbit anti-
human TRAIL (c-terminal) (ab42121, Abcam) anti-
body and primary mouse anti-CD9, anti-CD81 and
anti-CD63 antibodies (Invitrogen, UK). An HRP-con-
jugated secondary antibody against rabbit or mouse
IgG (Cell Signaling Technology, UK) was used accord-
ingly. Signals were detected with the Amersham ECL
plus western blot detection system (GE Healthcare).
Cell treatment and apoptosis analysis
Cancer cells or HBECs were plated at 8000 cells per
well in 96-well plates and cultured for overnight, then
were treated with agents for 24 h to examine agent
cytotoxicity. The tested agents include MSC-EVs,
MSCTRAIL-EVs (MSCT-EVs), recombinant TRAIL
(rTRAIL; amino acids 114–281, Peprotech), the pan-
caspase inhibitor Z-VAD-FMK (1 mg/ml, Sigma), a
neutralising monoclonal anti-TRAIL antibody (10 ng/
ml, Sigma, Cat. No. T3067), a CDK9 selective inhibi-
tor SNS032 (S1145, Selleckchem, UK) (300 nmol/l)
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and control medium, which were added to culture
medium in combination or alone. After treatment,
both floating and adherent cells were collected and
stained with AF647-conjugated Annexin V
(Invitrogen) and 2 μg/ml DAPI (Sigma), followed by
cell death assessment by means of flow cytometry.
Annexin V+/DAPI− cells were considered to have
undergone early apoptosis, Annexin V+/DAPI+ stain-
ing considered as late apoptosis, Annexin V−/DAPI+
cells considered to be dead not by apoptosis and both
Annexin V and DAPI negative cells were regarded as
viable. In parallel, cell apoptosis was also assessed
using the Annexin V-PE/7-AAD cell apoptosis assay
kit (Cat: 559763, BD-Pharmingen) following the man-
ufacturer’s instructions.
Active caspase-8 staining
Cancer cells were treated for 24 h with rTRAIL or EVs
to induce apoptosis. The treated cells were then har-
vested and stained with the active caspase-8 inhibitor
Red-IETD-FMK that was conjugated to sulfo-rhoda-
mine (K198-25, Bio-Vision) according to the manufac-
turer’s instructions. Subsequently, the stained cells
were analysed for active caspase-8 expression by
means of flow cytometry.
Statistical analysis
Data were analysed with the use of GraphPad Prism 6
software (GraphPad Software), one-way ANOVA fol-
lowed by Dunnett’s post-test or with Student’s t-test.
Significant probability values are denoted as * p < 0.05,
** p < 0.01 and *** p < 0.001.
Results
Isolation and characterisation of MSC-derived EVs
We have previously established TRAIL-overexpressing
MSCs (MSCTRAIL cells) that express both membra-
nous and secreted TRAIL [40,44–46]. It has been
shown that TRAIL can be an EV cargo released into
the extracellular milieu by some types of cells under
certain conditions [4,43,47]. We therefore hypothesise
that MSCTRAIL cells mass-produce and secrete func-
tional TRAIL-loaded EVs.
To validate this hypothesis we first isolated and
characterised MSC-derived EVs. EVs were isolated
from medium conditioned by MSCs or by
MSCTRAIL cells by sequential ultracentrifugation
combined with 0.22 μm ultrafiltration and were exam-
ined with transmission electron microscopy. As shown
in Figure 1(a) the obtained product appears as mem-
brane-enclosed vesicles of approximately 50–70 nm in
diameter, of similar morphology to that previously
observed [48,49]. The isolated EVs were subsequently
labelled with the lipid membrane dye PKH67, were
taken up by MDAMB231 (M231) cells and were visua-
lised using fluorescence microscopy (Figure 1(b)). The
prepared EVs were also labelled with a FITC-conju-
gated anti-CD63 antibody and were analysed by flow
cytometry. The isolated vesicles were more than 80%
CD63-positive, indicating that exosomes were mainly
extracted by this preparation route (Figure 1(c)). These
CD63+ EVs were purified following binding to mag-
netic beads coated with monoclonal CD63 antibody.
The purified MSC- and MSCTRAIL-derived vesicle-
bead complexes were labelled with PE- or AF647-con-
jugated isotype antibodies (Figure 2(a)), or antibodies
against CD9, CD63 or CD81 and were shown to be
CD63-, CD9- and CD81-positive by flow cytometry
(Figure 2(b,c)), further confirming their exosomal
property. Interestingly, CD81 showed the highest
expression level on isolated vesicles, CD63 in the mid-
dle and CD9 expressed the lowest levels of expression
on isolated vesicles (see supplementary Figure 1
online). Finally, EV production was measured for
MSCs, MSCs transduced with empty lentiviruses
(MSCEV) and MSCTRAIL cells using a commercial
kit. Interestingly, results showed that TRAIL-expres-
sing MSCs release significantly more EVs
(10.61 ± 2.62 × 108 EVs per h per 1 × 106 cells) than
both MSCs (2.21 ± 0.52 × 108) and MSCEVs
(2.29 ± 0.47 × 108) whilst MSCs and MSCEV cells
showed similar EV release (Figure 2(d)).
MSCTRAIL-derived EVs express membranal TRAIL
We next examined TRAIL expression in prepared
MSCTRAIL-derived EVs using a highly specific commer-
cial ELISA. The results showed that 38.8 ± 4.4 pg of
TRAIL was expressed in 1 μg of MSCTRAIL-derived
EV proteins (MSCT-EV); by contrast, MSC-derived
EVs (MSC-EV) showed no detectable TRAIL expression
(Figure 3(a)). MSCT-EVs were purified with beads coated
with CD63 antibody and TRAIL expression was analysed
by flow cytometry using a PE-conjugated TRAIL-specific
antibody. Results confirmed that CD63+ MSCT-EVs
express TRAIL (96.5% ± 2.8% positive) whilst MSC-EVs
were negative for TRAIL expression (1.95% ± 0.5% posi-
tive) (Figure 3(b)). TRAIL expression on MSCT-EVs was
also examined by western blotting. As shown in Figure 3
(c), TRAIL was expressed in MSCT-EVs as a single band
of ~70 kDa, which potentially corresponds to a hexameric
form of TRAIL [4]. By contrast, the major fraction of
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TRAIL in theMSCTRAIL cellular lysate was resolved as a
band of ~35 kDa and only a minor fraction presented as a
70-kDa band. The tetraspanins CD63, CD81 and CD9
were also detected by western blotting in analysed EVs,
confirming that the isolated vesicles were mostly exo-
somes (Figure 3(c)).
Using a commercial ELISA, TRAIL expression was
compared between MSCT-EVs and their originating
cells (Figure 3(d)). The results showed significantly
higher TRAIL expression in MSCT-EVs (38.8 ± 4.4 pg
TRAIL per 1 μg of EV proteins) than in MSCTRAIL cells
(26.2 ± 3.53 pg TRAIL per 1 μg of cellular proteins),
suggesting the relative enrichment of TRAIL molecules
in EVs. Taken together, these data demonstrate that
MSCs, when transduced to express TRAIL, can release
TRAIL into the extracellular environment via EVs.
TRAIL delivery by MSCT-EVs induces apoptosis in
cancer cells
The isolated EVs were used to treat the breast adenocar-
cinoma line M231, the lung adenocarcinoma cell line
A549 and primary normal human bronchial epithelial
cells (HBECs) to test their cytotoxic activity on these
cells. No cytotoxic effects were observed on HBECs
after MSC-EV, MSCT-EV or rTRAIL treatment
(Figure 4(a)). By contrast, rTRAIL and MSCT-EV
induced apoptosis in M231 cells in a dose-dependent
manner, whilst no cell killing was observed with the
MSC-EV control (Figure 4(b)). Interestingly, TRAIL pre-
sented by MSCT-EVs is more efficient at cancer cell
killing than rTRAIL as 100 µg/ml MSCT-EV that con-
tains 3.88 ng TRAIL/ml induced significantly more
apoptosis in M231 cells compared with 100 ng/ml of
rTRAIL (Figure 4(b)). As seen in Figure 4(c) and con-
sistent with previous observations [40,50], the A549 cell
line is fully resistant to rTRAIL. However, TRAIL deliv-
ery by MSCT-EVs induced significant apoptosis in A549
cells in a dose-dependent manner (Figure 4(c)). The
A549 killing capacity of MSCT-EVs was confirmed
using both Annexin V/DAPI and Annexin V/7-AAD
methods, which both showed similar apoptosis-inducing
activity of TRAIL-expressing EVs on A549 cells (supple-
mentary Figure 2(a–f)).
The pan-caspase inhibitor Z-VAD-FMK and the
TRAIL-neutralising antibody T3067 were tested on
M231 cells, either alone or together with MSCT-EVs.
Results showed that inhibition of caspase activity or
neutralisation of TRAIL significantly reduced MSCT-
EV-induced apoptosis in M231 cells whilst inhibitor or
Figure 1. Isolation and characterisation of MSC-derived extracellular vesicles (MSC-EVs). (a) Negative contrast micrograph of MSC-
EVs examined and imaged by transmission electron microscopy (TEM), scale bar 100 nm. (b) EVs were labelled by the lipid
membrane dye PKH67 (green) and taken up by MDAMB231 (M231) cells, followed by confocal microscopy examination; nuclei of
M231 cells were labelled with DAPI (blue). (c) Flow cytometry analysis of EVs. EVs were labelled with a FITC-conjugated antibody
against CD63 and compared with those labelled with a control FITC-isotype antibody. Top, a representative dot plot of at least three
experiments showing the percentage of CD63-expressing EVs among the tested sample; bottom, quantitation of median fluorescent
intensity (MFI) of labelled EVs.
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antibody only showed no effects (Figure 4(d)), suggest-
ing that the pro-apoptotic activity of MSCT-EVs is
caspase dependent and requires the engagement of
TRAIL receptors. Taken together, these data demon-
strate that TRAIL delivery by MSCT-EVs efficiently
induces apoptosis in cancer cells.
MSCT-EVs overcome TRAIL resistance of cancer
cells
The cytotoxic activity of MSCT-EVs was further exam-
ined in a panel of 11 established cancer cell lines,
consisting of 3 lung cancer lines (A549, NCI-H460
and NCI-H727), 4 mesothelioma lines (H2795,
H2804, H2810 and H2818), 2 renal cancer lines
(RCC10 and HA7-RCC), 1 breast cancer line (M231)
and 1 neuroblastoma line (SHEP-TET). These cell lines
were first treated with rTRAIL (100 ng/ml) and showed
varying levels of sensitivity in their response (Figure 5
(a,b)). They were grouped accordingly into those that
were rTRAIL sensitive (apoptosis ≥35%; 6 cell lines
including H2795, SHEP-TET, M231, NCI-H460, NCI-
H727 and H2804) or those that were rTRAIL resistant
(apoptosis ≤15%; 5 cell lines including A549, H2810,
H2818, HA7-RCC and RCC10). These two groups of
cell lines were then treated with MSCT-EVs and MSC-
EVs (100 µg/ml EV proteins) and analysed for the
induction of apoptosis using flow cytometry. In the
treatment of TRAIL-sensitive cell lines, MSCT-EVs
showed effective apoptosis induction (70% ± 28%),
although levels were only slightly higher than those
induced by rTRAIL (55% ± 15%). MSC-EVs induced
levels of apoptosis that were not different to control.
Interestingly, in the treatment of TRAIL-resistant cell
lines in which rTRAIL did not induce significant levels
of apoptosis, MSCT-EVs were capable of causing apop-
totic cell death where MSC-EVs were not although the
efficacy greatly varied between different cell lines
(Figure 5(b)). Apoptosis induction rates for individual
cancer cell lines were shown in supplementary Figure 3
(a,b) to distinguish which cell lines responded well or
Figure 2. Flow cytometry analysis of tetraspanin CD63, CD9 and CD81 expression on purified EVs, which were captured and purified
with magnetic latex beads coated with mAb against CD63 and labelled with PE-conjugated antibodies; the labelling was done in
detergent-free buffer aiming for EV surface protein labelling only. (a) Purified EV-bead complexes were stained with IgG-PE and IgG-
AF647 isotype antibodies. (b) EV-bead complexes were labelled with CD63-AF647 and CD81-PE antibodies. (c) EV-bead complexes
were labelled with CD63-AF647 and CD9-PE antibodies. (d) EV quantification showed that MSCTRAIL cells released more EVs than
parental MSCs and empty vector lentivirus-transfected cells (MSCEV). EV number was determined by measuring the EV-enriched
acetyl-CoA acetylcholinesterase (AChE) activity with a commercial EV quantification kit, values are mean ± SEM, n = 4; ** p < 0.01,
by Student’s t-test.
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not to treatment. DR4 and DR5 are responsible for the
TRAIL signalling pathway. To investigate if cancer cell
sensitivity to TRAIL is linked with DR4 and DR5
expression, all the tested cancer cell lines and a normal
HBECs were examined for DR4 and DR5 expression
using PE-conjugated antibody surface staining and
FACS analysis. The results showed that all tested cell
lines express DR4 and DR5 but with greatly varying
levels (supplementary Figure 4(a,b)). Both sensitive and
resistant groups show higher DR5 expression levels
than DR4, however no significant differences in DR4
or DR5 expression were revealed between the two
groups. Therefore cancer cell sensitivity to TRAIL
treatment may be associated with multiple factors, not
only with DR4 and DR5 expression levels.
Cell uptake of EVs was quantitated by FACS and
compared within two sensitive lines M231 and H2795
and two resistant lines A549 and H2810. The results
revealed no significant uptake differences either
between rTRAIL-sensitive and resistant cell lines or
between MSC-EVs and MSCT-EVs (supplementary
Figure 5(a,b)), indicating that the cytotoxicity of
MSCT-EVs on TRAIL-resistant cell lines is not due to
higher cellular uptake of EVs.
Figure 3. Detection of TRAIL and tetraspanin expression in isolated MSC-EVs. (a) Measurement of TRAIL expression in EVs with a
commercial ELISA kit. (b) Flow cytometry analyses of TRAIL and CD63 expression in purified EVs. MSC- and MSCT-EVs were purified
with latex beads coated with CD63 antibody and labelled with IgG-PE, IgG-AF647 or TRAIL-PE and CD63-AF647 antibodies,
respectively. (c) Western blotting detection of TRAIL and tetraspanin CD63, CD9 and CD81 in EVs and MSCTRAIL lysates; for each
sample 30 µg of cellular proteins or 20 µg of EV proteins were analysed; EV preparation of medium without cell culture and 1 ng of
rTRAIL (amino acids 114–281, PeproTech, USA) were used as negative and positive controls, respectively. (d) Comparison of TRAIL
expression levels in MSCs, MSCTRAILs and MSCT-EVs using a commercial TRAIL-specific ELISA kit. Values are mean ± SEM, n = 4; **
p < 0.01.
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In addition, apoptosis induction was accompanied by
activation of caspase-8 in TRAIL-resistant cells treated
with MSCT-EVs but not with MSC-EVs or rTRAILs
(Figure 5(c), shown for A549 cells), which confirmed
the delivery of a pro-apoptotic signal by MSCT-EVs.
CDK9 inhibition has been shown to synergise with
TRAIL treatment to induce apoptosis in TRAIL-resistant
cancer cells [50]. We therefore tested the combinational
treatment of MSCT-EVs and a CDK9 inhibitor, SNS032,
in TRAIL-resistant A549 cells [51]. As shown in Figure 5
(d), while the low concentration of MSCT-EVs (10 µg/ml
proteins) alone only showed very limited cancer cell-
killing activity (19.3% ± 2.1%), the combination of
MSCT-EVs and SNS032 greatly enhanced the level of
apoptosis induction (82.5% ± 8.3%).
We have therefore demonstrated that MSCT-EVs
can be used as broad-spectrum anticancer agents,
which are capable of at least partially overcoming
TRAIL-resistance in cancer cells.
Discussion
In this work we show that TRAIL-transduced MSCs
secrete EVs expressing surface TRAIL molecules
(MSCT-EVs), that MSCT-EVs are highly efficient at
selectively inducing apoptosis in cancer cells and that
delivery of TRAIL by MSCT-EVs at least partially over-
comes TRAIL resistance in cancer cells.
In this study MSC-EVs were prepared using ultra-
centrifugation combined with 0.22 μm filtration aiming
to preferentially isolate exosomes. The results showed
that ˃80% of isolated vesicles were CD63+ exosomes
expressing TRAIL, suggesting our preparation is
mainly composed of exosomes. Although this method
Figure 4. MSCT-EVs induced apoptosis of cancer cells with high efficiency. Cells were cultured in 96-well plate and treated for 24 h
with MSC-EVs or MSCT-EVs with concentrations varying from 1.0 to 100.0 µg/ml, or treated with 1.0–100.0 ng/ml rTRAIL, followed
by cell harvesting and labelling with Annexin V-AF647 and DAPI for apoptosis assay by flow cytometry. (a) Treatment of primary
human bronchial epithelial cells (HBECs). (b) Treatment of M231 cells. (c) Treatment of A549 cells. (d) Treatment of M231 cells with
100 ng/ml of TRAIL-neutralising monoclonal antibody (Ab) (T3067, Sigma-Aldrich) alone, 20 µmol/l of pan-caspase inhibitor Z-VAD-
FMK (inhib) alone, or with MSCT-EVs (100 µg/ml) alone, or with MSCT-EVs in combination with Ab (MSCT-EV+Ab) or with inhibitor
(MSCT-EV+inhib). Data represent averages ±S.E.M, n = 4. * p < 0.05, ** p < 0.01 compared with MSC-EV control, by one-way ANOVA
followed by Dunnett’s post-test.
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removes any microvesicles bigger than 220 nm, it is
impossible to separate exosomes from microvesicles of
smaller sizes (below 220 nm). However, the prepara-
tion can be further purified by sucrose density gradient
ultracentrifugation as exosomes have a higher sucrose
density (1.13–1.19 g/ml) compared with that of micro-
vesicles (1.04–1.07 g/ml).
Studies from other groups suggest that the source of
MSCs from which the EVs are produced could be
important in determining whether the MSC-EVs exert
anticancer activities or promote tumour growth. For
example, human umbilical cord Wharton’s jelly MSC
(hWJMSC)-derived EVs have been demonstrated to
reduce T24 bladder carcinoma growth [52]. Similarly,
EVs isolated from normal human bone marrow (BM)-
MSCs were reported to suppress cell cycle progression
and to induce apoptosis in liver carcinoma (HepG2)
and Kaposi’s cells [53]. However, Roccaro et al. [54]
found that BM-MSC-EVs from patients with multiple
myeloma could promote multiple myeloma tumour/
cell growth, whereas EVs from BM-MSCs isolated
from healthy patients inhibited the growth of multiple
myeloma tumour/cells both in vitro and in vivo. So, for
the therapeutic production of EVs, it will be important
to start with an appropriate source of MSCs to avoid
possible adverse effects.
TRAIL secretion via EVs seems to be a natural
approach used by certain types of cells to modulate
the function and behaviour of target cells at local or
at distant sites. For example, human Jurkat and normal
T cells, upon activation by phytohemagglutinin (PHA)
or by an anti-CD59 antibody, release TRAIL-bearing
Figure 5. MSCT-EVs efficiently killed rTRAIL-resistant cancer cell lines. (a) Six rTRAIL-sensitive cancer cell lines (H2795, H2804, NCI-
H460, NCI-H727, SHEP-TET and M231) were cultured in 96-well plates and treated with MSC-EVs (100 µg/ml), MSCT-EVs (100 µg/ml),
rTRAIL (100 ng/ml) or with control medium for 24 h, followed by analysis by cell apoptosis assay. (b) Five rTRAIL-resistant cancer cell
lines (H2810, H2818, HA7-RCC, RCC10 and A549) were treated with same agents like in (a) and analysed for cell apoptosis. (c)
Caspase-8 activity was examined by flow cytometry in A549 cells, which were treated with MSC-EVs (100 µg/ml proteins), MSCT-EVs
(100 µg/ml proteins) or with rTRAIL (100 ng/ml) for 24 h. Treated cells were labelled with the active caspase-8 binding dye Red-
IETD-FMK and analysed by flow cytometry. (d) CDK9 inhibition by SNS032 drastically enhanced apoptosis induction in A549 cells by
MSCT-EVs. Cell were treated with MSC-EV (10 µg/ml), MSCT-EV (10 µg/ml) or SNS032 (300 nmol/l) alone or with MSCT-EV (10 µg/ml)
in combination with SNS032 (300 nmol/l) for 24 h, and analysed by cell apoptosis assay. Data represent averages ± SEM, n = 4. *
p < 0.05, *** p < 0.001, analysed by Student’s t-test.
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EVs [55]. Also, human placental syncytiotrophoblasts
secrete TRAIL-loaded EVs, which induce apoptosis in
activated immune cells [4]. In addition, human color-
ectal cancer cells were found to secrete TRAIL-expres-
sing exosomes, resulting in the suppression of
surrounding immune cells [47]. All of these cells can
be potentially used for production of TRAIL-carrying
EVs. However, MSC-derived EVs may be the best
choice considering their good stability [20,21], high
modification flexibility in vitro and in vivo [14,22,23],
inherent therapeutic benefits and high tolerance
[24–26].
MSCs do not normally express endogenous TRAIL
[40], but upon stimulation with TNF-α, MSCs express
membrane-bound TRAIL but not the secreted type
[56]. Here we demonstrate that TRAIL-transduced
MSCs secrete TRAIL-carrying EVs. Interestingly,
TRAIL-transduced MSCs showed enhanced overall
EV secretion compared with untransduced MSCs or
empty vector lentivirus-transfected MSCs. The under-
lying enhancing mechanism is not clear but the endo-
plasmic reticulum (ER) stress-related enhancement of
protein secretion via EVs might be involved [57–59].
TRAIL in its soluble recombinant form, i.e. rTRAIL,
has been extensively tested for cancer therapy both in
vitro and in vivo. As demonstrated previously
[40,44,46] and also in this study, rTRAIL shows a
relatively low efficiency for cancer cell killing compared
with MSC- or MSC-EV-mediated delivery of TRAIL.
The clinical trials that have so far been carried out
using rTRAIL had used a high administration dose of
up to 30 mg kg−1, possibly because of its limited bioa-
vailability and low activity; despite this, the obtained
therapeutic benefits were poor [39]. Resistance to this
ligand is another reason for its poor clinical perfor-
mance in cancer treatment [39]. However, the high
cancer cell-killing efficiency shown by TRAIL-expres-
sing MSCT-EVs in this study indicates that TRAIL
delivery by EVs may improve the clinical performance
of TRAIL. It is not clear why EV-displayed TRAIL is
more efficient at inducing apoptosis than the recombi-
nant soluble type. We also noticed that TRAIL-expres-
sing MSCs are much more effective in inducing
apoptosis than rTRAIL [40,44]. It was recently shown
that higher order clustering of TRAIL receptors may be
necessary for effective activation of the extrinsic death
pathway [60,61]. Indeed, TRAIL oligomerisation has
been demonstrated to be necessary for its efficient
induction of apoptosis in target cells [62]. TRAIL mole-
cules expressed in MSCT-EVs or by MSCs are localised
on the lipid membrane and therefore possibly allow
higher order clustering of the ligand to take place as a
result of movements permitted by the fluidic nature of
the bilayer lipid membrane; this could be the reason
why MSCT-EVs induce more apoptosis in target cells
than rTRAIL.
In addition to their superior TRAIL-presenting effi-
ciency, as drug delivery vehicles EVs have other attrac-
tive advantages. First, EVs are natural nanoparticles
that may infiltrate a wide range of tissues following
systemic administration. It has been reported that
EVs can even cross the brain-blood barrier to deliver
their cargoes [14]. Second, there is a high degree of
flexibility in how EVs can be modified both in vitro
and in vivo. As demonstrated in this study, MSCs can
be genetically modified to produce EVs loaded with
therapeutic molecules such as TRAIL. Third, drugs or
siRNAs can be directly loaded into prepared EVs [22]
or applied to parental cells and incorporated during the
biogenesis of EVs [63]. For example, MSCs treated with
paclitaxel have been shown to take up the drug and to
later secrete paclitaxel-loaded EVs, which are capable
of inhibiting human pancreatic adenocarcinoma
(CFPAC-1) cell proliferation and of reducing tumour
growth by up to 50% [63]. In this study we show that
combinational treatment of cancer cells with MSCT-
EVs and the CDK9 inhibitor SNS032 drastically
enhanced cancer cell-killing efficacy. In the future it
would be really interesting to test whether loading
SNS032, paclitaxel, TRAIL-sensitising siRNA or other
small therapeutic molecules into the prepared TRAIL-
expressing MSCT-EVs could have even greater or pos-
sibly synergistic anticancer efficacies in vitro and in
vivo.
Finally, EVs have an inherent homing ability allow-
ing them to migrate towards damaged tissues or can-
cers in vivo [64]. For example, EVs, when systemically
administered, were found to home to xenograft breast
cancer tissues in mice [65]. The underlying mechanism
remains unclear although an acidic pH within solid
tumours may increase EV uptake [66]. Moreover, EVs
can be engineered to increase their tumour tropism. El-
Andaloussi et al. [22] have demonstrated that dendritic
cell (DC)-derived EVs can be engineered to fuse a
neuron-specific RVG peptide to the EV membrane
protein LAMP2B, resulting in enhanced brain homing.
Similarly, EVs can be modified to display an epidermal
growth factor receptor (EGFR)-binding peptide GE11
on their surface for targeted delivery of a therapeutic
miRNA to xenograft breast cancer tissues that express
EGFR [65]. EGFR is overexpressed or aberrantly acti-
vated in many tumours including lung adenocarci-
noma [67], suggesting that EGFR could serve as a
target in the EV-based cancer drug delivery system.
While our prepared TRAIL-bearing EVs are still to be
investigated for their tumour-homing properties and
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their anticancer efficacy in vivo, it could be possible to
enhance their cancer-targeting capacity by fusing
tumour antigen-binding peptides such as GE11 to the
EV membrane.
Taken together, results indicate that TRAIL-expres-
sing MSCT-EVs could potentially be developed into an
innovative anticancer therapy.
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